AI English summary of an SEC filing — figures as filed

The company said revenue for December 31, 2024 in fiscal 2025 Q1 rose 12.8% year over year to $81.5 billion. It cited growth of 13.6% in the U.S. Healthcare Solutions segment's revenue as the main factor.

8-KResults of Operations and Financial ConditionFiled Feb 5, 2025Period of report Feb 5, 2025Summary published (UTC) Oct 8, 2026

Key points

AI summary

The company said revenue for December 31, 2024 in fiscal 2025 Q1 rose 12.8% year over year to $81.5 billion. It cited growth of 13.6% in the U.S. Healthcare Solutions segment's revenue as the main factor.
Cencora said GAAP diluted earnings per share for Q1 were $2.50, below $2.98 a year earlier, while adjusted diluted EPS was $3.73, up 13.7% from $3.28 a year earlier.
The company said it raised its adjusted diluted EPS outlook for fiscal 2025 to $15.25 to $15.55 from the prior range of $15.15 to $15.45. It said the change reflects continued momentum in the U.S. Healthcare Solutions segment.
Cencora said it completed its acquisition of Retina Consultants of America (RCA) on January 2, 2025. It said it issued $1.8 billion in senior notes in December 2024 to help fund part of the acquisition.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

Revenue of $81.5 billion for Q1 of fiscal 2025, up 12.8%

The company said revenue for December 31, 2024 in fiscal 2025 Q1 rose 12.8% year over year to $81.5 billion. It cited growth of 13.6% in the U.S. Healthcare Solutions segment's revenue as the main factor.

Source · Based on the filing body and exhibits

Cencora Reports Q1 GAAP Diluted EPS of $2.50, Adjusted Diluted EPS of $3.73

Cencora said GAAP diluted earnings per share for Q1 were $2.50, below $2.98 a year earlier, while adjusted diluted EPS was $3.73, up 13.7% from $3.28 a year earlier.

Source · Based on the filing body and exhibits

Fiscal 2025 Adjusted Diluted EPS Outlook Range Changed

The company said it raised its adjusted diluted EPS outlook for fiscal 2025 to $15.25 to $15.55 from the prior range of $15.15 to $15.45. It said the change reflects continued momentum in the U.S. Healthcare Solutions segment.

Source · Based on the filing body and exhibits

Retina Consultants of America Acquisition and Senior Notes Issuance

Cencora said it completed its acquisition of Retina Consultants of America (RCA) on January 2, 2025. It said it issued $1.8 billion in senior notes in December 2024 to help fund part of the acquisition.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.